This is an archive article published on January 27, 2021
Premium

AstraZeneca’s Covid-19 vaccine testing stumble draws investor lawsuit 

Alleging "wrongful acts and omissions" by the company and its chief officers, the pension fund is asking to be allowed to sue on behalf of a class of all investors injured by the share price decline.

AstraZeneca, AstraZeneca antibody trials, Coronavirus vaccine, Covid-19 vaccine, Antibody, Indian expressVials of the AstraZeneca Plc and the University of Oxford Covid-19 vaccine at the Royal Health & Wellbeing Centre in Oldham, U.K., on Thursday, Jan. 21, 2021. (Bloomberg Photo: Anthony Devlin)
2 min readJan 27, 2021 10:07 AM IST First published on: Jan 27, 2021 at 10:07 AM IST

AstraZeneca PLC was sued by a pension fund on behalf of investors who it says suffered losses because of flaws in the company’s testing of its coronavirus vaccine.

For much of last year, the Cambridge, England-based pharmaceutical company was touting strong progress on the development of its traditional-style vaccine and announced that it had signed contracts to provide 400 million doses. But in November, questions emerged about the vaccine when the company released initial test results.

Advertisement

Among other things, experts and health officials faulted the testing for a lack of data on the vaccine’s effectiveness for those 55 and older. They also raised questions about results from one trial that found the vaccine 90 per cent effective for subjects who got a half a dose but only 62 per cent effective for those who got the full dose.

Latest Comment
Post Comment
Read Comments